Paricalcitol alleviates intestinal ischemia-reperfusion injury via inhibition of the ATF4-CHOP pathway [PDF]
Frontiers in PharmacologyIntroductionIntestinal ischemia reperfusion (I/R) injury is a severe condition characterized by inflammation, oxidative stress, and compromised intestinal barrier function, which can lead to death.
Jiawei Zhang +3 more
doaj +2 more sources
Effects of Paricalcitol on Renal Secondary Hyperparathyroidism and Proteinuria in Dogs With Chronic Kidney Disease [PDF]
Journal of Veterinary Internal MedicineBackground Renal secondary hyperparathyroidism (RHPT) is an inevitable consequence of chronic kidney disease (CKD). Paricalcitol might safely attenuate RHPT and proteinuria.
Hilla Chen +2 more
doaj +2 more sources
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism [PDF]
Kidney International, 2003 Management of secondary hyperparathyroidism has included the use of active vitamin D or vitamin D analogs for the suppression of parathyroid hormone (PTH) secretion. Although, these agents are effective, therapy is frequently limited by hypercalcemia, hyperphosphatemia, and/or elevations in the calcium-phosphorus (Ca x P) product.
Stuart M Sprague +2 more
exaly +3 more sources
Paricalcitol prevents MAPK pathway activation and inflammation in adriamycin-induced kidney injury in rats [PDF]
Journal of Pathology and Translational MedicineBackground Activation of the mitogen-activated protein kinase (MAPK) pathway induces uncontrolled cell proliferation in response to inflammatory stimuli.
Amanda Lima Deluque +8 more
doaj +2 more sources
Anti-inflammatory profile of paricalcitol in kidney transplant recipients
Nefrología (English Edition), 2017 Background and objectives: Paricalcitol, a selective vitamin D receptor activator, is used to treat secondary hyperparathyroidism in kidney transplant patients.
Javier Donate-Correa +8 more
doaj +3 more sources
Effects of Paricalcitol on Body Composition in Vitamin D-Deficient Rats [PDF]
Iranian Journal of Medical Sciences, 2021 Background: Paricalcitol has been proposed for the treatment of secondary hyperparathyroidism in patients with renal failure and vitamin D deficiency (VDD); however, VDD is related to a range of clinical complaints. We aimed to investigate the effects of
Farhad Koohpeyma +3 more
doaj +1 more source
Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin. [PDF]
PLoS ONE, 2017 The aim of this study was to assess any potential additive effects of a treatment combining aliskiren with paricalcitol on reducing renal fibrosis. C57BL/6J mice were treated individually with aliskiren and/or paricalcitol until 7 days after initiation ...
Sungjin Chung +7 more
doaj +1 more source
Neuroprotective effect of paricalcitol in a rat model of transient global cerebral ischemia
International Journal of Emergency Medicine, 2020 Background Paricalcitol is known to attenuate ischemic-reperfusion injury of various organs. However, it is not known whether paricalcitol prevents neuronal injury after global cerebral ischemia.
Sung Wook Kim +6 more
doaj +1 more source
Paricalcitol for reduction of albuminuria in diabetes [PDF]
The Lancet, 2011 1raises several concerns. First, little attention is given to the fact that the primary endpoint— ie, the eff ect of the vitamin D receptor activator (VDRA) on urinary albuminto-creatinine ratio (UACR)—is actually negative. The positive results on secondary endpoints should thus be used only to generate new hypotheses, not to support the effi cacy of ...
Pierre Delanaye +3 more
+5 more sources
Paricalcitol attenuates 4-hydroxy-2-hexenal-induced inflammation and epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. [PDF]
PLoS ONE, 2013 4-Hydroxy-2-hexenal (HHE), the aldehyde product of lipid peroxidation, may be responsible for the pathogenesis of progressive renal disease. Recently, paricalcitol (19-nor-1,25-dihydroxyvitamin D2) was shown to be renoprotective through its anti ...
Chang Seong Kim +8 more
doaj +1 more source